Is it time to include p40 as a standard myoepithelial marker of breast? A comparative study of expression of p63 and p40 in benign breast diseases and invasive ductal carcinomas of the breast
Clinical Cancer Investigation Journal · 2021 · 10 (2) · 78-83
DOI: 10.51847/j0rdem4kqd893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cancer Investigation Journal, 2021. Verfasst von Richa Ranjan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ranjan, R., Gupta, A., Singh, S., Cheriaparambath, A., & Singh, R. (2021). Is it time to include p40 as a standard myoepithelial marker of breast? A comparative study of expression of p63 and p40 in benign breast diseases and invasive ductal carcinomas of the breast. Clinical Cancer Investigation Journal, 10(2), 78-83. https://doi.org/10.51847/j0rdem4kqd893
Vancouver
Ranjan R, Gupta A, Singh S, Cheriaparambath A, Singh R. Is it time to include p40 as a standard myoepithelial marker of breast? A comparative study of expression of p63 and p40 in benign breast diseases and invasive ductal carcinomas of the breast. Clinical Cancer Investigation Journal. 2021;10(2):78-83. doi:10.51847/j0rdem4kqd893
BibTeX
@article{Ranjan2021,
author = {Ranjan, Richa and Gupta, Alpana and Singh, Samresh and Cheriaparambath, Aatirah and Singh, Raj},
title = {Is it time to include p40 as a standard myoepithelial marker of breast? A comparative study of expression of p63 and p40 in benign breast diseases and invasive ductal carcinomas of the breast},
journal = {Clinical Cancer Investigation Journal},
year = {2021},
volume = {10},
number = {2},
pages = {78--83},
doi = {10.51847/j0rdem4kqd893}
}
EUVIMED